Cormorant Asset Management, LP Eye Point Pharmaceuticals, Inc. Transaction History
Cormorant Asset Management, LP
- $628 Million
- Q3 2025
A detailed history of Cormorant Asset Management, LP transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 8,325,000 shares of EYPT stock, worth $98.7 Million. This represents 18.35% of its overall portfolio holdings.
Number of Shares
8,325,000
Previous 8,325,000
-0.0%
Holding current value
$98.7 Million
Previous $78.3 Million
47.08%
% of portfolio
18.35%
Previous 7.9%
Shares
5 transactions
Others Institutions Holding EYPT
# of Institutions
168Shares Held
68MCall Options Held
454KPut Options Held
401K-
Suvretta Capital Management, LLC New York, NY6.19MShares$73.4 Million2.57% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.56MShares$65.9 Million0.13% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.42MShares$52.3 Million0.12% of portfolio
-
Franklin Resources Inc San Mateo, CA4.17MShares$49.4 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.79MShares$45 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $404M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...